INmune Bio Inc.
INMBHealthcareNASDAQBiotechnology · Last scanned Oct 23, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, INmune Bio Inc. focuses on Biotechnology services and products. INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. The $42.7M market capitalization puts INMB squarely in micro-cap range for its industry. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.
Market Cap
$42.7M
Beta
0.90
P/E (TTM)
—
P/E (Fwd)
-3.58
EPS (TTM)
$-0.64
EPS (Fwd)
$-0.43
ROE
-74.8%
ROA
-39.1%
Cash
$18.4M
Total Debt
$1.4M
Free CF
-$10.0M
52W Change
-14.0%
Annual Financials
Cash vs Debt
Where INMB stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, INMB finished 8.88% below its 150-day moving average ($1.69) and 6.10% below its 200-day moving average ($1.64). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is INMB overbought or oversold?
At the October 20, 2026 close, INMB's RSI(14) was 18.2, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
INmune Bio Inc. holds $18.4M in cash against $1.4M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$10.0M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -74.8%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $374K (2022) to $50K (2025), a 87% decline worth watching.
With cash comfortably exceeding debt, INMB has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing INMB's risk profile alongside its fundamentals and technical indicators provides a more complete picture.